Medical Devices; Gastroenterology-Urology Devices; Classification of the Non-Medicated Topical Formulation for Treatment of Erectile Dysfunction
Key claim: The FDA is classifying non-medicated topical formulations for treatment of erectile dysfunction as class II medical devices with special controls to provide reasonable assurance of safety and effectiveness while reducing regulatory burdens.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the non- medicated topical formulation for treatment of erectile dysfunction into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the non-medicated topical formulation for treatment of erectile dysfunction. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
This final rule creates a defined 510(k) pathway for non-medicated topical ED products, allowing manufacturers to market such devices without the more burdensome premarket approval process required for Class III devices. For patients, it may expand access to over-the-counter or prescription topical options while ensuring baseline safety and effectiveness through special controls.